Darunavir is a protease inhibitor antiviral medicine that prevents Human Immunodeficiency Virus (HIV-1) from multiplying in the body
Almost 300 million people globally have chronic hepatitis B
Revenue in the three months ended on Oct. 1 also slipped by 42% to US$ 13.23 billion
Merck continues progress in helping to protect people at risk of Zaire ebolavirus disease
Bayer reported the highest market capitalization growth of 23.1% during Q1 2023
he product will be launched shortly in the US market.
FDA also accepts a separate supplemental application to extend prophylaxis with PREVYMIS to 200 days in certain HSCT recipients
OmiCrisp has been developed with support from Centre for Cellular And Molecular Platforms C-CAMP-InDx Program
WHO made a strong recommendation for nirmatrelvir and ritonavir for mild and moderate COVID-19 patients at highest risk of hospital admission
Separate Phase 3 study evaluating 200 days of therapy with PREVYMIS in HSCT recipients at high risk of late clinically significant CMV infection recently completed, meeting its primary endpoint
Subscribe To Our Newsletter & Stay Updated
